'Single Dose' CanSino Vaccine from China Shows 66% Effectiveness

[Image source=Reuters Yonhap News]

[Asia Economy Reporter Cho Hyun-ui] The COVID-19 vaccine developed by Chinese biotechnology company CanSino Biologics has been found to have a preventive efficacy of 65.7%.

On the 9th (local time), according to Bloomberg and Global Times, Faisal Sultan, Special Advisor to the Prime Minister of Pakistan on Health, disclosed the preliminary results of CanSino vaccine's Phase 3 clinical trial the day before.

The efficacy in preventing severe COVID-19 was 90.9%. Advisor Sultan stated, "No serious safety concerns were found in the clinical trial involving 30,000 participants."

The preventive efficacy of the CanSino COVID-19 vaccine is lower than that of China's Sinopharm (78%) but higher than Sinovac (50.4%). It is significantly lower than the vaccines currently administered worldwide such as Pfizer (95%), Moderna (94.1%), and AstraZeneca (70.8%).

Unlike many other vaccines that require two doses, the CanSino vaccine is administered in a single dose, similar to the Janssen vaccine. Furthermore, it can be stored refrigerated for two years, which is advantageous for distribution and administration.

The CanSino vaccine has not yet received general use approval in China. Clinical trials are currently underway in Pakistan, Mexico, Russia, Argentina, and Chile.

It has been agreed to supply 35 million doses to Mexico, and Pakistan will receive 20 million doses.

CanSino is undergoing the World Health Organization (WHO) vaccine approval process to enable distribution of its vaccine through the international vaccine procurement project 'COVAX Facility.'

This content was produced with the assistance of AI translation services.